SUCCESSOR-2
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 525 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs), Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1320
- NCT Identifier
- NCT05552976
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.